Diabetic Peripheral Neuropathy Therapeutics Research 2024: Comprehensive Insights about 10+ Companies and 15+ Pipeline Drugs [Yahoo! Finance]
Lexicon Pharmaceuticals, Inc. (LXRX)
Last lexicon pharmaceuticals, inc. earnings: 4/27 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
lexpharma.com/investors
Company Research
Source: Yahoo! Finance
This "Diabetic Peripheral Neuropathy- Pipeline Insight, 2024" report provides comprehensive insights about 10+ companies and 15+ pipeline drugs in Diabetic Peripheral Neuropathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. "Diabetic Peripheral Neuropathy- Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diabetic Peripheral Neuropathy pipeline landscape is provided which includes the disease overview and Diabetic Peripheral Neuropathy treatment guidelines. The assessment part of the report embraces, in depth Diabetic Peripheral Neuropathy commercial assessment and clinical assessment of the pipeline products under development. In the report,
Show less
Read more
Impact Snapshot
Event Time:
LXRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LXRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LXRX alerts
High impacting Lexicon Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
LXRX
News
- Diabetic Neuropathic Pain Treatment Landscape 2024: Comprehensive Insights About 10+ Companies and 12+ Pipeline Drugs - Product Type, Stage, Route of Administration, and Molecule Type [Yahoo! Finance]Yahoo! Finance
- Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.MarketBeat
- Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 DiabetesGlobeNewswire
- Data From Lexicon's RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association [Yahoo! Finance]Yahoo! Finance
- Data From Lexicon’s RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes AssociationGlobeNewswire
LXRX
Earnings
- 5/2/24 - Miss
LXRX
Sec Filings
- 5/16/24 - Form EFFECT
- 5/14/24 - Form 4
- 5/14/24 - Form SC
- LXRX's page on the SEC website